Clinical trials: Hip Osteoarthritis
Osteoarthritis, Hip
Study to Evaluate a Procedure for Intra-articular Injection of FX006 in Patients With Osteoarthritis of the Hip
This is a multi-center, single-arm, open-label study of FX006 in patients with hip OA. A maximum number of approximately 30 patients may be enrolled in this protocol.
- Trial name
- NCT04065074
- Testing
- FX006 32 mg
- Where
- 5 sites in United States
- Volunteers
- 16 people
- Sponsor
- Pacira Pharmaceuticals, Inc
Osteoarthritis
Prospective Multicenter Non-interventional Study in Patients With Knee or Hip Osteoarthritis Having a Theraflex Treatment
The main purpose of this study is to evaluate how a long-term treatment with Theraflex during 64 weeks affects pain intensity in the affected knee or hip joint, the activity in daily living, the quality of life and patient…
- Trial name
- NCT03330288
- Testing
- Theraflex, BAY 874017
- Where
- 2 sites in Russia
- Volunteers
- 1,102 people
- Sponsor
- Bayer
Osteoarthritis
Extension Study Of Tanezumab In Osteoarthritis
Safety extension study of Phase 3 Osteoarthritis trials with Tanezumab
- Trial name
- NCT00809783
- Testing
- tanezumab
- Where
- 226 sites in United States
- Volunteers
- 2,147 people
- Sponsor
- Pfizer
Osteoarthritis, Hip, Rheumatoid Arthritis
Avenir Müller Hip Stem Post Market Surveillance Study
This study is a Post Market Clinical Follow up study to fulfil the post market surveillance obligations according to Medical Device Directive and European Medical Device Vigilance System (MEDDEV) 2.12-2.
- Conditions
- Osteoarthritis, Hip, Rheumatoid Arthritis, Fracture of Hip, Dislocated Hip
- Trial name
- NCT04079127
- Testing
- Patients who met the inclusion/exclusion criteria to receive the Avenir Müller stem.
- Volunteers
- 150 people
- Sponsor
- Zimmer Biomet
Osteoarthritis, Hip
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
The primary objective of this study was to demonstrate any changes in assessments of pain for participants receiving Synvisc-One compared to control.
- Trial name
- NCT01618708
- Testing
- Synvisc-One (hylan G-F 20)
- Where
- 48 sites in United States, Canada
- Volunteers
- 357 people
- Sponsor
- Genzyme, a Sanofi Company
Osteoarthritis, Knee, Osteoarthritis, Hip
Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee
The primary purpose of this study is to evaluate the efficacy of a titration arm of tanezumab in which treatment is started at a lower dose (2.5 mg) and increased to a higher dose (5 mg) at Week 8, compared to giving 2 doses of…
- Trial name
- NCT02697773
- Testing
- Tanezumab 2.5 mg, Tanezumab 2.5mg/5mg
- Where
- 87 sites in United States, Canada and 1 more
- Volunteers
- 698 people
- Sponsor
- Pfizer
Arthritis, Osteoarthritis
Tanezumab in Osteoarthritis Of The Hip
The purpose of this study is to test the efficacy and safety of 3 doses of tanezumab in osteoarthritis of the hip in patients
- Conditions
- Arthritis, Osteoarthritis, Osteoarthritis, Hip
- Trial name
- NCT00744471
- Testing
- tanezumab
- Where
- 99 sites in United States
- Volunteers
- 627 people
- Sponsor
- Pfizer
Joint Diseases
28 mm Ceramic-on-Ceramic Acetabular Cup Total Hip Replacement Study
The study is designed to evaluate artificial hips with a 28 mm ceramic head and a ceramic liner to determine whether they perform as well as artificial hips with a 28 mm ceramic head and a polyethylene liner.
- Trial name
- NCT00208507
- Testing
- 28 mm ceramic head on ceramic acetabular liner., 28 mm ceramic head on polyethylene liner
- Where
- 2 sites in United States
- Volunteers
- 264 people
- Sponsor
- DePuy Orthopaedics
Chronic Pain
A Double-blind Study of Controlled Release OROS Hydromorphone Compared to Placebo in Patients With Chronic Osteoarthritis (OA) Pain
To evaluate the efficacy of OROS Hydromorphone in reducing moderate to severe chronic pain in patients with Osteoarthritis (OA) Pain
- Trial name
- NCT00631319
- Testing
- OROS hydromorphone
- Volunteers
- 343 people
- Sponsor
- Mallinckrodt
Osteoarthritis
Study of Meloxicam Capsules in Subjects With Osteoarthritis of the Knee or Hip
The purpose of this study is to evaluate the safety of Meloxicam SoluMatrix Capsules for up to 52 weeks in subjects with pain due to osteoarthritis (OA) of the knee or hip
- Trial name
- NCT01801735
- Testing
- Meloxicam Test Capsules
- Where
- 40 sites in United States
- Volunteers
- 600 people
- Sponsor
- Iroko Pharmaceuticals, LLC
Osteoarthritis, Hip, Osteoarthritis, Knee
Study of the Analgesic Efficacy and Safety of Subcutaneous Tanezumab in Subjects With Osteoarthritis of the Hip or Knee.
Tanezumab is a monoclonal antibody that binds to and inhibits the actions of nerve growth factor (NGF). The Nerve Growth Factor Inhibitor (NGFI) class may offer an important breakthrough in the treatment of chronic pain and is…
- Trial name
- NCT02709486
- Testing
- Tanezumab
- Where
- 148 sites in Austria, Bulgaria and 13 more
- Volunteers
- 849 people
- Sponsor
- Pfizer
Non-inflammatory Joint Diseases
Metal on Metal Versus Ceramic on Metal Hip Replacement
The purpose of this study is to compare the performance of artificial hips with metal heads and metal sockets to artificial hips with ceramic heads articulating with metal socket components.
- Trial name
- NCT00208494
- Testing
- Total Hip Replacement
- Where
- 9 sites in United States, Canada
- Volunteers
- 392 people
- Sponsor
- DePuy Orthopaedics
Osteoarthritis, Knee, Osteoarthritis, Hip
Study to Evaluate the Effects of Fasinumab on Peripheral Nerve Function in Patients With Pain Due to Osteoarthritis of the Hip or Knee
The primary objective of the study is to evaluate the effect of fasinumab compared to placebo on peripheral nerves in participants with pain due to Osteoarthritis (OA) of the hip or knee.
- Trial name
- NCT03691974
- Testing
- Fasinumab
- Where
- 47 sites in United States, Poland and 1 more
- Volunteers
- 180 people
- Sponsor
- Regeneron Pharmaceuticals
Osteoarthritis, Avascular Necrosis
Trilogy AB Acetabular Hip System Post Approval Study
This is a post-approval study with prospective enrollment in the United States and a retrospective enrollment outside the United States to obtain functional, quality of life and radiographic data, which will facilitate assessment…
- Conditions
- Osteoarthritis, Avascular Necrosis, Congenital Hip Dysplasia, Traumatic Arthritis
- Trial name
- NCT00715026
- Testing
- Trilogy AB Acetabular Hip Implant System
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- Zimmer Biomet
Osteoarthritis, Knee, Osteoarthritis, Hip
Study Of "Continuous Use" Of Celecoxib Vs. "Usual or Intermittent Use"
To determine whether "continuous use" of celecoxib over a 6-month period is more efficacious than "usual or intermittent use" in preventing spontaneous osteoarthritis flares of the knee and hip.
- Trial name
- NCT00139776
- Testing
- Celecoxib
- Where
- 124 sites in United States, Belgium and 6 more
- Volunteers
- 875 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Degenerative Hip Joint Disease, Rheumatoid Arthritis (RA)
Study to Evaluate the Safety and Efficacy of OR3O™ Dual Mobility System vs. Conventional Single Bearing Design Total Hip System
The purpose of this study is to compare OR3O™ Dual Mobility System to a conventional, single-bearing design Total Hip System in subjects who undergo Primary THA.
- Conditions
- Degenerative Hip Joint Disease, Rheumatoid Arthritis (RA), Femoral Neck Fractures, Avascular Necrosis of Femoral Head
- Trial name
- OR3O (NCT04941729)
- Testing
- OR3O™ - Dual Mobility System, Conventional
- Where
- 4 sites in China
- Volunteers
- 24 people
- Sponsor
- Smith & Nephew Medical (Shanghai) Ltd
Hip Osteoarthritis
OXINIUM◊ DH Total Hip Arthroplasty Pivotal Study
The purpose of this study is to monitor safety of the participants implanted with the OXINIUM◊ DH Hip System up to 10-years post-implantation
- Trial name
- NCT02353377
- Testing
- OXINIUM DH Hip System, BIOLOX◊
- Volunteers
- 413 people
- Sponsor
- Smith & Nephew, Inc.
Osteoarthritis
Buprenorphine in the Treatment of Osteoarthritis (OA) in the Elderly
The primary objective is to compare buprenorphine transdermal delivery system (BTDS) with standard- treatment in subjects with osteoarthritis (OA).
- Trial name
- NCT00324038
- Testing
- Buprenorphine, Codeine paracetamol
- Where
- United Kingdom
- Volunteers
- 219 people
- Sponsor
- Napp Pharmaceuticals Limited
Osteoarthritis of the Hip
The MONOVISC Hip Osteoarthritis Study
This study is being done to determine the effectiveness of MONOVISC for the relief of pain and symptoms of osteoarthritis of the hip.
- Trial name
- NCT02698865
- Testing
- MONOVISC, Saline
- Where
- 27 sites in United States
- Volunteers
- 220 people
- Sponsor
- DePuy Mitek
Osteoarthritis, Hip, Osteoarthritis, Knee
A Study Evaluating Pain Relief and Safety of Orally Administered CR845 in Patients With Osteoarthritis of Hip or Knee
The study schedule consists of a Screening Period (up to 14 days), a blinded 4- week Titration-to-Effect Period with weekly visits, a blinded 4-week Maintenance Treatment Period at the optimal dose level determined for each…
- Conditions
- Osteoarthritis, Hip, Osteoarthritis, Knee, Arthritis, Joint Diseases
- Trial name
- NCT02944448
- Testing
- CR845 tablet 1 mg, CR845 tablet 2.5 mg, CR845 tablet 5 mg
- Where
- 35 sites in United States
- Volunteers
- 761 people
- Sponsor
- Cara Therapeutics, Inc.